Following closely on the heels of the news that its deal to merge Pfizer’s consumer health business with its own, GSK has announced that Nucala (mepolizumab) had secured approval from the European Commission for two new...
Latest articles
EMA committee recommends approval of Merck’s Zerbaxa 3g dose to treat adults with HAP, including VAP
Merck, known as MSD outside the United States and Canada, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending...
NICE recommends Pierre Fabre’s Nerlynx in adjuvant HER2+ breast cancer
Pierre Fabre’s Nerlynx (neratinib) has been recommended by NICE as a new option for NHS patients with early hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The ruling...
‘Marketing equals overhead’: Why marketing is still seen as a cost-center
Despite chief marketing officers making the case for how important marketing is to an overall business, marketing’s reputation as a “cost center,” versus one that actually drives profits, is hard to shake off. Earlier...
Biogen & Alkermes’ multiple sclerosis drug proves ‘statistically superior’ to Tecfidera at Phase 3
Biogen and Alkermes have unveiled new Phase 3 data for diroximel fumarate, comparing the adequacy of the therapy to Biogen’s own Tecfidera (dimethyl fumarate) in the treatment of patients with relapsing-remitting...
ViiV seeks EU marketing nod for cabotegravir in combo with rilpivirine as first monthly, injectable treatment for HIV
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced the submission of a marketing authorisation application (MAA) to the
